2,936 results match your criteria Sentinel Lymph Node Biopsy in Patients With Melanoma

Presence of Dendritic Cell Subsets in Sentinel Nodes of Breast Cancer Patients Is Related to Nodal Burden.

Int J Mol Sci 2022 Jul 30;23(15). Epub 2022 Jul 30.

General, Oncological and Gastrointestinal Surgery, Jagiellonian University Medical College, 31-008 Cracow, Poland.

Background: Sentinel lymph nodes (SLNs) are both the first site where breast cancer (BC) metastases form and where anti-tumoral immunity develops. Despite being the most potent antigen-presenting cells, dendritic cells (DCs) located in a nodal tissue can both promote or suppress immune response against cancer in SLNs.

Methods: In SLNs excisions obtained from 123 invasive BC patients, we performed immunohistochemistry (IHC) for CD1a, CD1c, DC-LAMP, and DC-SIGN to identify different DCs populations. Read More

View Article and Full-Text PDF

Metastasis of melanoma in non-sentinel nodes in patients with metastatic sentinel node. Can we avoid complementary lymphadenectomy?

Cir Cir 2022 ;90(4):525-528

Departamento de Tumores de Cabeza y Cuello, Hospital de Oncología, Centro Médico Nacional Siglo XXI, Ciudad de México, México.

Background: Lymph mapping with sentinel node biopsy is the standard procedure for lymph node staging in patients with cutaneous melanoma with a tumor thickness of 1 mm or greater. Patients who have metastases in sentinel node must undergo complementary lymphadenectomy; however, it has not been shown to improve survival.

Objective: To know the prevalence in our setting of metastases in the product of complementary lymphadenectomy in patients with metastatic sentinel node. Read More

View Article and Full-Text PDF

Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial.

JAMA Surg 2022 Aug 3. Epub 2022 Aug 3.

Department of Dermatology, University of Lubeck, Lubeck, Germany.

Importance: Sentinel lymph node (SLN) biopsy is a standard staging procedure for cutaneous melanoma. Regional disease control is a clinically important therapeutic goal of surgical intervention, including nodal surgery.

Objective: To determine how frequently SLN biopsy without completion lymph node dissection (CLND) results in long-term regional nodal disease control in patients with SLN metastases. Read More

View Article and Full-Text PDF

Interventional Ultrasound in Dermatology: A Pictorial Overview Focusing on Cutaneous Melanoma Patients.

J Ultrasound Med 2022 Aug 3. Epub 2022 Aug 3.

Radiology Unit, Varelli Diagnostic Institute, Naples, Italy.

Cutaneous melanoma incidence is increasing worldwide, representing an aggressive tumor when evolving to the metastatic phase. High-resolution ultrasound (US) is playing a growing role in the assessment of newly diagnosed melanoma cases, in the locoregional staging prior to the sentinel lymph-node biopsy procedure, and in the melanoma patient follow-up. Additionally, US may guide a number of percutaneous procedures in the melanoma patients, encompassing diagnostic and therapeutic modalities. Read More

View Article and Full-Text PDF

Association of type II diabetes mellitus with characteristics and outcomes for patients undergoing sentinel lymph node biopsy for cutaneous melanoma.

J Surg Oncol 2022 Jul 28. Epub 2022 Jul 28.

Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Background And Objectives: Type II diabetes mellitus (T2DM) can lead to an immunosuppressed state, but whether T2DM is associated with worse outcomes for patients with melanoma has not been well studied.

Methods: Consecutive patients diagnosed with clinical stage I-II cutaneous melanoma who underwent sentinel lymph node biopsy at a single institution (2007-2016) were identified. Melanoma characteristics and recurrence/survival outcomes were compared between patients with and without T2DM at the time of melanoma diagnosis. Read More

View Article and Full-Text PDF

Subcostal lymph nodes: An unusual sentinel lymph node basin in cutaneous melanoma.

J Surg Oncol 2022 Jul 23. Epub 2022 Jul 23.

Department of Surgery, University of Virginia, Charlottesville, Virginia, USA.

Background And Objectives: Lymphatic drainage from subcostal nodes, along the costal groove, have not previously been characterized as sites for melanoma drainage and metastasis. This study reports a series of patients with subcostal nodes draining primary melanomas, with characterization of the sites of primary melanomas that drain to these nodes.

Methods: Patients who presented to our institution between 2005 and 2020 with documented cutaneous melanoma and sentinel lymph node biopsy of a subcostal node (sentinel = S), or metastases to subcostal nodes later in clinical management (recurrent = R) were included. Read More

View Article and Full-Text PDF

An Internally Validated Prognostic Risk-Score Model for Disease-Specific Survival in Clinical Stage I and II Merkel Cell Carcinoma.

Ann Surg Oncol 2022 Jul 22. Epub 2022 Jul 22.

Division of Endocrine and Oncologic Surgery, Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.

Background: Merkel cell carcinoma (MCC) is a rare cutaneous malignancy for which factors predictive of disease-specific survival (DSS) are poorly defined.

Methods: Patients from six centers (2005-2020) with clinical stage I-II MCC who underwent sentinel lymph node (SLN) biopsy were included. Factors associated with DSS were identified using competing-risks regression analysis. Read More

View Article and Full-Text PDF

Local delivery of low-dose anti-CTLA-4 to the melanoma lymphatic basin leads to systemic T reduction and effector T cell activation.

Sci Immunol 2022 07 15;7(73):eabn8097. Epub 2022 Jul 15.

Amsterdam UMC location Vrije Universiteit, Medical Oncology, De Boelelaan 1117, 1081 HV, Amsterdam, Netherlands.

Preclinical studies show that locoregional CTLA-4 blockade is equally effective in inducing tumor eradication as systemic delivery, without the added risk of immune-related side effects. This efficacy is related to access of the CTLA-4 blocking antibodies to tumor-draining lymph nodes (TDLNs). Local delivery of anti-CTLA-4 after surgical removal of primary melanoma, before sentinel lymph node biopsy (SLNB), provides a unique setting to clinically assess the role of TDLN in the biological efficacy of locoregional CTLA-4 blockade. Read More

View Article and Full-Text PDF

Tilmanocept as a novel tracer for lymphatic mapping and sentinel lymph node biopsy in melanoma and oral cancer.

ANZ J Surg 2022 Jul 18. Epub 2022 Jul 18.

Faculty of Medicine, Department of Surgical Oncology and Head and Neck Surgery, Crown Princess Mary Cancer Centre, University of Sydney, Sydney, New South Wales, Australia.

Background: Sentinel lymph node biopsy (SLNB) has been pivotal for pathological assessment of nodal status in cutaneous melanoma (CM) and oral cavity squamous cell carcinoma (OCSCC) thus crucial for staging. An ideal agent for lymphatic mapping should have a standardized preparation, appropriate accumulation in first-echelon nodes and no side effects. Tilmanocept, a CD206-receptor targeted novel radiotracer fulfils these properties. Read More

View Article and Full-Text PDF

Does It Really Pay-Off? Comparison of Lymphadenectomy versus Observational Approach in Skin Melanoma with Positive Sentinel Node Biopsy: Systematic Review and Meta-Analysis.

J Clin Med 2022 Jul 4;11(13). Epub 2022 Jul 4.

Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, Gustawa Herlinga-Grudzińskiego 1, 30-705 Krakow, Poland.

The aim of this meta-analysis was to answer the question as to whether performing CLND (complete lymph node dissection) is necessary in every case of the melanoma patient after the positive SNB (sentinel node biopsy). To resolve doubts the authors reanalyzed previous articles and systematized the knowledge about the concerning medical problem. The databases such as PubMed, Scopus and Web of Science were screened to find articles that will be helpful to answer the controversial question if performing lymphadenectomy is crucial. Read More

View Article and Full-Text PDF

Predictive factors of melanoma thickness.

An Bras Dermatol 2022 Jun 25. Epub 2022 Jun 25.

Faculty of Medicine, Universidade de Coimbra, Coimbra, Portugal; Dermatological Surgery Unit, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.

Background: Melanoma thickness is a relevant prognostic marker that is crucial for staging and its calculation relies on the histopathological examination. There is a risk of thickness underestimation with an incisional biopsy if the latter is not performed on a tumor area where the thickness is maximal. This occurrence may have an impact on a therapeutic decision, particularly regarding the excision margins and the need for sentinel lymph node biopsy. Read More

View Article and Full-Text PDF

In-transit metastasis of cutaneous squamous cell carcinoma: report of two cases.

Acta Dermatovenerol Alp Pannonica Adriat 2022 Jun;31(2):75-77

Department of Dermatology and Venereology, Haydarpaşa Numune Training and Research Hospital, Istanbul, Turkey.

Transit metastases include metastatic foci of the skin and subcutaneous tissue located between the tumor and the nearest regional lymph node. Although transit metastases have been described for malignant melanoma, some cases of transit metastases have also been reported among primary cutaneous non-melanoma cancers. Treatment of patients with in-transit squamous cell carcinoma (SCC) is a multimodal approach for advanced staging imaging and therapy, including Mohs micrographic surgery, adjuvant radiation, and possibly sentinel lymph node biopsy and immunotherapy or chemotherapy. Read More

View Article and Full-Text PDF

Does Residual Invasive Disease in Wide Local Excision after Diagnosis with Partial Biopsy Technique Influence Survival in Melanoma? Matched-Pair Analysis of Multicenter Selective Lymphadenectomy Trial I and II.

J Am Coll Surg 2022 Jul 5;235(1):49-59. Epub 2022 May 5.

From Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA.

Background: Current guidelines recommend excisional/complete biopsy for melanoma diagnosis, owing to high rates of residual disease found at wide local excision (WLE) after partial biopsy techniques. We sought to determine any survival disadvantage associated with the presence of residual invasive melanoma in the WLE after diagnosis with a partial biopsy technique.

Study Design: Data were examined from Multicenter Selective Lymphadenectomy Trials I and II (MSLT-I and -II), 2 large melanoma trials. Read More

View Article and Full-Text PDF

Population-based assessment of sentinel lymph node biopsy in the management of cutaneous melanoma.

Can J Surg 2022 May-Jun;65(3):E394-E403. Epub 2022 Jun 14.

From the University of British Columbia, Vancouver, BC (Ollek, Minkova, Taqi, Chen, Martinka); and the British Columbia Cancer Agency, Vancouver, BC (Davis, Hamilton, Stuart).

Background: Sentinel lymph node biopsy (SLNB) for melanoma plays a central role in determining prognosis and guiding treatment and surveillance strategies. Despite widely published guidelines for SLNB, variation exists in its use. We aimed to determine the frequency of and predictive factors for SLNB in patients with clinically node-negative melanoma in British Columbia. Read More

View Article and Full-Text PDF

Predictors of Sentinel Lymph Node Metastasis in Patients with Thin Melanoma: An International Multi-institutional Collaboration.

Ann Surg Oncol 2022 Jun 8. Epub 2022 Jun 8.

Department of Surgery, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Background: Consideration of sentinel lymph node biopsy (SLNB) is recommended for patients with T1b melanomas and T1a melanomas with high-risk features; however, the proportion of patients with actionable results is low. We aimed to identify factors predicting SLNB positivity in T1 melanomas by examining a multi-institutional international population.

Methods: Data were extracted on patients with T1 cutaneous melanoma who underwent SLNB between 2005 and 2018 at five tertiary centers in Europe and Canada. Read More

View Article and Full-Text PDF

A Novel Fascial Flap Technique After Inguinal Complete Lymph Node Dissection for Melanoma.

J Surg Res 2022 Oct 4;278:356-363. Epub 2022 Jun 4.

Department of Surgery, University of Virginia Health System, Charlottesville, Virginia. Electronic address:

Introduction: Inguinal complete lymph node dissection (CLND) for metastatic melanoma exposes the femoral vein and artery. To protect femoral vessels while preserving the sartorius muscle, we developed a novel sartorius and adductor fascial flap (SAFF) technique for coverage.

Methods: The SAFF technique includes dissection of fascia off sartorius and/or adductor muscles, rotation over femoral vasculature, and suturing into place. Read More

View Article and Full-Text PDF
October 2022

The role of sentinel node tumor burden in modeling the prognosis of melanoma patients with positive sentinel node biopsy: an Italian melanoma intergroup study (N = 2,086).

BMC Cancer 2022 Jun 3;22(1):610. Epub 2022 Jun 3.

Soft-Tissue, Peritoneum and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV- IRCCS, 35128, Padua, Italy.

Background: The management of melanoma patients with metastatic melanoma in the sentinel nodes (SN) is evolving based on the results of trials questioning the impact of completion lymph node dissection (CLND) and demonstrating the efficacy of new adjuvant treatments. In this landscape, new prognostic tools for fine risk stratification are eagerly sought to optimize the therapeutic path of these patients.

Methods: A retrospective cohort of 2,086 patients treated with CLND after a positive SN biopsy in thirteen Italian Melanoma Centers was reviewed. Read More

View Article and Full-Text PDF

Breslow thickness 2.0: Why gene expression profiling is a step toward better patient selection for sentinel lymph node biopsies.

Mod Pathol 2022 Jun 2. Epub 2022 Jun 2.

Department of Dermatology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.

Risk-stratification of cutaneous melanoma is important. Patients want to know what to expect after diagnosis, and physicians need to decide on a treatment plan. Historically, melanoma that had spread beyond the skin and regional lymph nodes was largely incurable, and the only approach to preventing a bad outcome was surgery. Read More

View Article and Full-Text PDF

Real-World Adherence to Nodal Surveillance for Sentinel Lymph Node-Positive Melanoma.

Ann Surg Oncol 2022 Sep 24;29(9):5961-5968. Epub 2022 May 24.

Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.

Background: Patients with sentinel lymph node-positive (SLN+) melanoma are increasingly undergoing active nodal surveillance over completion lymph node dissection (CLND) since the Second Multicenter Selective Lymphadenectomy Trial (MSLT-II). Adherence to nodal surveillance in real-world practice remains unknown.

Methods: In a retrospective cohort of SLN+ melanoma patients who underwent nodal surveillance at a single institution from July 2017 through April 2021, this study evaluated adherence to nodal surveillance ultrasound (US). Read More

View Article and Full-Text PDF
September 2022

Opioid-Free Segmental Thoracic Spinal Anesthesia with Intrathecal Sedation for Breast and Axillary Surgery: Report of Four Cases.

Local Reg Anesth 2022 9;15:23-29. Epub 2022 May 9.

Department of Anaesthesiology, IRCSS-INRCA, Ancona, Italy.

Purpose: Few studies have described segmental thoracic spinal anesthesia (STSA) as primary anesthesiologic method in breast and axillary surgery, documenting the association of intrathecal local anesthetics and opioids. This case series reports an opioid-free scheme of STSA in four elderly patients undergoing major breast and axillary oncological surgery.

Patients And Methods: STSA was performed in three female patients undergoing unilateral mastectomy ± axillary lymph node dissection (ALND) or sentinel lymph node biopsy for invasive ductal carcinoma and in one male patient undergoing ALND for melanoma metastases. Read More

View Article and Full-Text PDF

Tetraspanin CD9 Expression Predicts Sentinel Node Status in Patients with Cutaneous Melanoma.

Int J Mol Sci 2022 Apr 26;23(9). Epub 2022 Apr 26.

Clinica Dermatologica, Dipartimento di Scienze Cliniche e Molecolari, Università Politecnica delle Marche, 60126 Ancona, Italy.

The tetraspanin CD9 is considered a metastasis suppressor in many cancers, however its role is highly debated. Currently, little is known about CD9 prognostic value in cutaneous melanoma. Our aim was to analyse CD9 expression in melanocytic nevi and primary cutaneous melanomas through immunohistochemistry and immunofluorescence approaches to determine its correlation with invasiveness and metastatic potential. Read More

View Article and Full-Text PDF

Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study.

Ann Surg Oncol 2022 Sep 13;29(9):5937-5945. Epub 2022 May 13.

H. Lee Moffitt Cancer Center, Tampa, Florida, USA.

Background: Patients presenting with early-stage melanoma (AJCC pT1b-pT2a) reportedly have a relatively low risk of a positive SNB (~5-10%). Those patients are usually found to have low-volume metastatic disease after SNB, typically reclassified to AJCC stage IIIA, with an excellent prognosis of ~90% 5-year survival. Currently, adjuvant systemic therapy is not routinely recommended for most patients with AJCC stage IIIA melanoma. Read More

View Article and Full-Text PDF
September 2022

Critical Review of the Sentinel Lymph Node Surgery in Malignant Melanoma.

J Drugs Dermatol 2022 05;21(5):510-516

Malignant melanoma is one of the most aggressive solid tumors but has low morbidity if treated at an early stage. Over the past decade, the advent of targeted therapy and immunotherapy have productively enriched the treatment options for advanced melanomas and further improved the prognosis. The treatment of melanoma is a rapidly evolving field. Read More

View Article and Full-Text PDF

Cutaneous Melanoma and Sentinel Lymph Node Biopsy: A Single-Center Retrospective Study of 331 Patients in Argentina.

Actas Dermosifiliogr 2022 03 6;113(3):332-335. Epub 2021 Oct 6.

Sección Cirugía de Cabeza y Cuello, Servicio de Cirugía General, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

View Article and Full-Text PDF

Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in the Second Multicenter Selective Lymphadenectomy Trial (MSLT-II).

Ann Surg Oncol 2022 Sep 2;29(9):5910-5920. Epub 2022 May 2.

Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Background: Minimally invasive inguinal lymphadenectomy (MILND) is safe and feasible, but limited data exist regarding oncologic outcomes.

Methods: This study performed a multi-institutional retrospective cohort analysis of consecutive MILND performed for melanoma between January 2009 and June 2016. The open ILND (OILND) comparative cohort comprised patients enrolled in the second Multicenter Selective Lymphadenectomy Trial (MSLT-II) between December 2004 and March 2014. Read More

View Article and Full-Text PDF
September 2022

Complete response of Merkel cell carcinoma with talimogene laherparepvec (TVEC) monotherapy.

Dermatol Online J 2022 Jan 15;28(1). Epub 2022 Jan 15.

Department of Dermatology, School of Medicine, University of New Mexico, Albuquerque, New Mexico, USA.

Merkel cell carcinoma (MCC) is a rare neuroendocrine neoplasm, warranting surgical excision with sentinel lymph node biopsy. In later stages, adjuvant chemotherapy and radiation are required owing to its aggressive malignant behavior. We describe a 62-year-old woman who presented with multifocal recurrence of MCC and was not a candidate for immunotherapy or surgery. Read More

View Article and Full-Text PDF
January 2022

Advantages of Sentinel Lymph Node Mapping by Single Photon Emission Computed Tomography/Computed Tomography in Early-Stage Malignant Head-and-Neck Skin Tumors.

Indian J Nucl Med 2022 Jan-Mar;37(1):43-49. Epub 2022 Mar 25.

Department of Epidemiology, National Cancer Institute, Bogotá, Colombia.

Background: The aim of this study was to determine the advantages of preoperative sentinel lymph node mapping (SLNM) by single photon emission computed tomography/computed tomography (SPECT / CT) in patients with early-stage cutaneous head-and-neck malignancies.

Materials And Methods: We conduct a 7-year and 6 months retrospective, cross-sectional study. Patients with early-stage malignant head-and-neck skin tumors and cutaneous adnexa who underwent SLNM by SPECT/CT from March 2012 and December 2019, were included in the study. Read More

View Article and Full-Text PDF

Utility of a Model for Predicting the Risk of Sentinel Lymph Node Metastasis in Patients With Cutaneous Melanoma.

JAMA Dermatol 2022 06;158(6):680-683

Gastric and Mixed Tumor Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.

Importance: A neural network-based model (i31-GEP-SLNB) that uses clinicopathologic factors (thickness, mitoses, ulceration, patient age) plus molecular analysis (31-gene expression profiling) has become commercially available to guide selection for sentinel lymph node (SLN) biopsy in cutaneous melanoma, but its clinical utility is not well characterized.

Objective: To determine if use of the i31-GEP-SLNB model is associated with clinical benefit when used to select patients for SLN biopsy.

Design, Setting, And Participants: This decision-analytic study used data derived from a published external validation study of the i31-GEP-SLNB prediction model. Read More

View Article and Full-Text PDF

Sentinel lymph node biopsy in patients with clinical stage IIB/C cutaneous melanoma: A national cohort study.

J Am Acad Dermatol 2022 Apr 22. Epub 2022 Apr 22.

Department of Surgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania.

Background: Approval of adjuvant anti-programmed cell death protein 1 therapy for pathologic stage IIB/C cutaneous melanoma has led some to question the role of sentinel lymph node (SLN) biopsy in the clinical stage IIB/C disease.

Objective: To determine the prognostic significance of SLN staging on disease-specific survival (DSS) for clinical stage IIB/C primary cutaneous melanoma in the preimmunotherapy era.

Methods: A retrospective cohort study was performed evaluating patients who underwent excision of clinical stage IIB/C cutaneous melanoma using the Surveillance, Epidemiology, and End Results database (2004-2011). Read More

View Article and Full-Text PDF